Articles by James Calloway
PVH Slashes Revenue Forecast, Shares Tumble 18.7% After Hours
PVH shares fell 18.7% after hours after the company slashed its full-year revenue forecast to roughly flat, citing ongoing pressure in the EMEA region.
Five Below Stock Tumbles Despite Strong Q1 Results as Investor Concerns Mount
Five Below shares plunged 12.6% in after-hours trading even after the discount retailer posted better-than-expected first-quarter results and lifted its full-year outlook.
Netskope Tumbles 20% in After-Hours Trading as Cash Flow Concerns Overshadow Revenue Growth
Netskope shares plunged 20% after hours to $9.96, despite a Q1 earnings beat, as negative free cash flow and slowing net new ARR overshadowed 28% revenue growth.
Veeva Systems Slips Despite Strong Earnings, AI Strategy in Focus
Veeva Systems shares declined 2.3% despite beating Q1 estimates and raising guidance, as investors assess AI spending and CRM migration risks.
C3.ai Shares Rebound After Earnings; Turnaround Efforts Under Scrutiny
C3.ai shares rose 2.2% after hours as fiscal Q4 revenue topped estimates, but fiscal 2027 revenue guidance fell short, keeping turnaround concerns alive.
CrowdStrike Beats Q1 Estimates, Shares Fall on Rising AI Costs
CrowdStrike shares plunged about 8% after hours on Wednesday, even as the cybersecurity firm beat Q1 revenue and earnings estimates and raised its full-year outlook, with AI-related costs climbing.
Medtronic Shares Surge on Strong Q4, Guidance Weighs
Medtronic shares jumped 5.4% after beating Q4 estimates on strong heart-device sales, but fiscal 2027 guidance missed due to tariff and diabetes split uncertainty.
Dine Brands Shutters Calexico Applebee's After 20-Year Run
Applebee's shuts its Calexico restaurant after two decades, putting 30 jobs at risk, as Dine Brands pivots to dual-branded Applebee's-IHOP locations amid inflation pressures.
Macy's Stock Flat Despite Q1 Beat, Bloomingdale's Drives Upbeat 2026 Outlook
Macy's raised its 2026 sales and profit forecasts after Q1 comparable sales rose 3.0%, but shares were little changed as investors weighed tariff and consumer risks.
Medtronic Surges on Strong Heart-Device Sales, But 2027 Profit Outlook Caps Gains
Medtronic shares surged 5.1% after beating Q4 estimates, fueled by 78% cardiac ablation growth, but gains were capped by a weak 2027 profit outlook and tariff concerns.
